Research programme: cancer therapeutics - Critical Outcome Technologies

Drug Profile

Research programme: cancer therapeutics - Critical Outcome Technologies

Alternative Names: COTI-04; COTI-219; COTI-4A; COTI-58

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Critical Outcome Technologies
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; KRAS protein inhibitors; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Proto oncogene protein c-akt inhibitors; Thymidylate synthase expression modulators; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Colorectal cancer
  • No development reported Cancer; Small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Canada (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in Canada (PO)
  • 28 Aug 2017 Critical Outcome Technologies intends to file an IND application with the US FDA for Cancer (COTI 219) in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top